Dichlorphenamide Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Feb 16, 2023.
Dichlorphenamide is also known as: Daranide, Keveyis
Dichlorphenamide Pregnancy Warnings
This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
US FDA pregnancy category: C
Teratogenic effects (fetal limb reduction defects) were reported following oral administration of this drug in pregnant animals during organogenesis at 350 mg/kg, or 17 times the maximum recommended human dose (200 mg/day) on a body surface area (mg/m2) basis. A no-effect dose has not been established. There are no adequate and well-controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Dichlorphenamide Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comment:
-The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
References for breastfeeding information
- "Product Information. Keveyis (dichlorphenamide)." Taro Pharmaceuticals U.S.A. Inc (2015):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.